Intravenous Iron: Not Just for Hemodialysis Patients Anymore

National Kidney Foundation. DOQI Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30(Suppl 3): S192–240.

Wish J.B. Assessing iron status: beyond ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S4–8.

National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3): S1–145.

Besarab A. , Amin N. , Ahsan M. , Vogel S.E. , Zazuwa G. , Frinak S. Optimization of epoetin therapy with intravenous iron supplementation in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530–8.

Besarab A. , Kaiser J.W. , Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34: 21–8.

Coyne D.W. , Kapoian T. , Suki W. , Singh A.K. , Moran J.E. , Dahl N.V. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975–84.

Pizzi L.T. , Patel N.M. , Maio V.M. , Goldfarb D.S. , Michael B. , Fuhr J.P. Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. Dial Transplant 2006; 35: 660–71.

National Kidney Foundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1): S182–238.

Hakim R.M. , Stivelman J.C. , Schulman G. , Fosburg M. , Wolfe L. , Imber M.J. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987; 10: 293–9.

Ali M. , Fayemi A.O. , Rigolosi R. , Frascino J. , Marsden T. , Malcolm D. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 1980; 244: 343–5.

Morrison E.D. , Brandhagen D.J. , Phatak P.D. , Barton J.C. , Krawitt E.L. , El-Serag H.B. Serum ferritin level predicts advanced hepatic fibrosis among U. S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627–33.

Bishu K. , Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S19–23.

Kalantar-Zadeh K. , Regidor D.L. , McAllister C.J. , Michael B. , Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070–80.

Hoen B. , Paul-Dauphin A. , Hestin D. , Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869–76.

Li H. , Wang S. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int 2008; 28: 149–54.

Besarab A. , Coyne D. , Bolton W.K. , Sharma A. , Foti A. , Brenner L. Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease [Abstract]. J Am Soc Nephrol 2007; 18: 762A.

Spinowitz B. , Kausz A. , Miller P. , Brenner L. , Singh A. Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [Abstract]. J Am Soc Nephrol 2007; 18: 814A.

Singh A. , Spinowitz B. , Provenzano R. , Bolton W.K. , Baptista J. , Pereira B. Safety of ferumoxytol as intravenous (IV) iron therapy for iron deficiency anemia [Abstract]. J Am Soc Nephrol 2007; 18: 291A.

Bolton W.K. , Besarab A. , Germain M. , Kovesdy C.P. , Hutchinson J. , Kausz A. Ferumoxytol as an IV iron replacement therapy: efficacy results from two phase III studies in patients with chronic kidney disease (CKD) [Abstract]. J Am Soc Nephrol 2007; 18: 761A.

Quinibi W. , Dinh Q. , Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM), a new high dose intravenous iron, across ten multi-center clinical trials [Abstract]. J Am Soc Nephrol 2007; 18: 813A–814A.

Quinibi W. , Martinez C. , Smith M. , Benjamin J. , Dinh Q. A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non dialysis-dependent CKD [Abstract]. J Am Soc Nephrol 2007; 18: 814A.

Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 2006; 101: S13–18.

Besarab A. , Bolton W.K. , Browne J.K. , Egrie J.C. , Nissenson A.R. , Okamoto D.M. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584–90.

Singh A.K. , Szczech L. , Tang K.L. , Barnhart H. , Sapp S. , Wolfson M. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–98.

General Accounting Office. End stage renal disease. Medicare payments for all ESRD services, including injectable drugs, should be bundled. Washington, DC: US Government Accountability Office; 2006: publication GA0-07-266T.

Wish J.B. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int Suppl 2006; 104: S21–5.